BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 12935435)

  • 1. Therapeutic and hemolytic evaluation of in-situ liposomal preparation containing amphotericin - beta complexed with different chemically modified beta - cyclodextrins.
    Chakraborty KK; Naik SR
    J Pharm Pharm Sci; 2003; 6(2):231-7. PubMed ID: 12935435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PHARMACOKINETIC STUDIES OF IN-SITU LIPOSOMAL PREPARATION CONTAINING AMPHOTERICIN B COMPLEXED WITH DIFFERENT CHEMICALLY MODIFIED beta-CYCLODEXTRINS.
    Chakraborty KK; Naik SR
    J Liposome Res; 2001; 11(1):1-14. PubMed ID: 19530915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In situ liposomal preparation containing amphotericin B: related toxicity and tissue disposition studies.
    Chakraborty KK; Naik SR
    Pharm Dev Technol; 2000; 5(4):543-53. PubMed ID: 11109253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model.
    Khan MA; Owais M
    J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The novel lipid delivery system of amphotericin B: drug profile and relevance to clinical practice.
    Rust DM; Jameson G
    Oncol Nurs Forum; 1998; 25(1):35-48. PubMed ID: 9460772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liposomal amphotericin-B in the control of experimental aspergillosis in mice: Part I--Relative therapeutic efficacy of free and liposomal amphotericin-B.
    Ahmad I; Sarkar AK; Bachhawat BK
    Indian J Biochem Biophys; 1989 Dec; 26(6):351-6. PubMed ID: 2698855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model.
    Olson JA; Adler-Moore JP; Schwartz J; Jensen GM; Proffitt RT
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2122-31. PubMed ID: 16723574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incorporation of amphotericin B in tuftsin-bearing liposomes showed enhanced efficacy against systemic cryptococcosis in leucopenic mice.
    Khan MA; Nasti TH; Owais M
    J Antimicrob Chemother; 2005 Oct; 56(4):726-31. PubMed ID: 16126780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of high loading doses of liposomal amphotericin B in the treatment of experimental invasive pulmonary aspergillosis.
    Gavaldà J; Martín T; López P; Gomis X; Ramírez JL; Rodríguez D; Len O; Puigfel Y; Ruiz I; Pahissa A
    Clin Microbiol Infect; 2005 Dec; 11(12):999-1004. PubMed ID: 16307554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemolytic and antifungal activity of liposome-entrapped amphotericin B prepared by the precipitation method.
    Kim JC; Lee EO; Kim JY; Bae SK; Choi TB; Kim JD
    Pharm Dev Technol; 1997 Aug; 2(3):275-84. PubMed ID: 9552455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis.
    Lewis RE; Liao G; Hou J; Chamilos G; Prince RA; Kontoyiannis DP
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1253-8. PubMed ID: 17261624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of high doses of liposomal amphotericin B in the treatment of experimental aspergillosis.
    Martín MT; Gavaldà J; López P; Gomis X; Ramírez JL; Rodríguez D; Len O; Jordano Q; Ruiz I; Rosal M; Almirante B; Pahissa A
    J Antimicrob Chemother; 2003 Dec; 52(6):1032-4. PubMed ID: 14613950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of liposomal amphotericin B formulation.
    Gulati M; Bajad S; Singh S; Ferdous AJ; Singh M
    J Microencapsul; 1998; 15(2):137-51. PubMed ID: 9532520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential or combination antifungal therapy with voriconazole and liposomal amphotericin B in a Guinea pig model of invasive aspergillosis.
    Kirkpatrick WR; Coco BJ; Patterson TF
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1567-9. PubMed ID: 16569887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapeutic efficiency of amphotericin B liposome modified by RMP-7 to transport drug across blood brain barrier].
    Zhang XB; Yuan S; Lei PC; Hou XP
    Yao Xue Xue Bao; 2004 Apr; 39(4):292-5. PubMed ID: 15303662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A pharmacodynamics study of an intravitreal amphotericin B drug delivery system for the treatment of experimental Aspergillus fumigatus endophthalmitis].
    Yang X; Dong XG; Liu AM; Sun SY; Xie LX; Wang SG
    Zhonghua Yan Ke Za Zhi; 2007 Jun; 43(6):546-53. PubMed ID: 17897534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative study on the efficacy of liposomal amphotericin B and voriconazole in a murine pulmonary aspergillosis model.
    Takemoto K; Yamamoto Y; Ueda Y; Kanazawa K; Yoshida K; Niki Y
    Chemotherapy; 2009; 55(2):105-13. PubMed ID: 19151551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of amphotericin B incorporated into liposomes and in lipid suspensions in the treatment of murine candidiasis.
    Kretschmar M; Nichterlein T; Hannak D; Hof H
    Arzneimittelforschung; 1996 Jul; 46(7):711-5. PubMed ID: 8842344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of alternative dosing regimens of poly-aggregated amphotericin B.
    Espada R; Valdespina S; Molero G; Dea MA; Ballesteros MP; Torrado JJ
    Int J Antimicrob Agents; 2008 Jul; 32(1):55-61. PubMed ID: 18534826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo distribution and therapeutic efficacy of a novel amphotericin B poly-aggregated formulation.
    Espada R; Valdespina S; Dea MA; Molero G; Ballesteros MP; Bolás F; Torrado JJ
    J Antimicrob Chemother; 2008 May; 61(5):1125-31. PubMed ID: 18285313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.